Product Description
Teduglutide injection is used to treat short bowel syndrome in people who need additional nutrition or fluids from intravenous (IV) therapy. Teduglutide injection is in a class of medications called glucagon-like peptide-2 (GLP-2) analogs. It works by improving the absorption of fluids and nutrients in the intestines. (Sourced from: https://medlineplus.gov/druginfo/meds/a613019.html)
Mechanisms of Action: GcGr Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Greece | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | United Kingdom | United States
Approved Indications: Short Bowel Syndrome
Known Adverse Events: Abdominal Pain | Pain Unspecified | Respiratory Tract Infections
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Japan
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Short Bowel Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2021210035 | P3 |
Active, not recruiting |
Short Bowel Syndrome |
2023-09-30 |
|
| TAK-633-3008 | P3 |
Completed |
Short Bowel Syndrome |
2023-09-27 |
|
| 2022-003572-16 | P3 |
Active, not recruiting |
Short Bowel Syndrome |
2023-02-08 |
|
| SHP633-307 | P3 |
Completed |
Short Bowel Syndrome |
2022-01-13 |